Drug news
CHMP recommends Aubagio (Sanofi/Genzyme) for Multiple Sclerosis
Sanofi and its subsidiary Genzyme have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion regarding the approval of once-daily, oral Aubagio (teriflunomide) for the treatment of adult patients with relapsing-remitting Multiple Sclerosis (MS). The CHMP did not recommend that Aubagio receive a new active substance designation.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.